Loading...
•
Sep 30, 2021
Astrana Health Q3 2021 Earnings Report
Announced consolidated financial results, reflecting revenue growth and strategic investments
Key Takeaways
Apollo Medical Holdings, Inc. reported a strong third quarter with a 26% increase in total revenue and a 105% increase in net income attributable to ApolloMed. The company also raised its full-year 2021 guidance due to continued organic growth and increased risk pool settlements and incentives revenue.
Q3 total revenue increased by 26% year-over-year to $227.1 million.
Q3 net income attributable to ApolloMed increased by 105% year-over-year to $34.3 million.
Q3 earnings per share (diluted) increased by 64% year-over-year to $0.74.
Full-year 2021 guidance was raised due to organic growth and increased risk pool settlements.
Revenue by Segment
Forward Guidance
ApolloMed raised its full-year 2021 guidance for total revenue, net income, net income attributable to ApolloMed, EBITDA, and adjusted EBITDA.
Positive Outlook
- Total revenue is projected to be between $751.5 million and $758.5 million.
- Net income is projected to be between $81.0 million and $83.5 million.
- Net income attributable to ApolloMed is projected to be between $71.5 million and $73.5 million.
- EBITDA is projected to be between $139.0 million and $143.0 million.
- Adjusted EBITDA is projected to be between $168.5 million and $170.5 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...